These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37993487)

  • 1. Morphologically-Directed Raman Spectroscopy as an Analytical Method for Subvisible Particle Characterization in Therapeutic Protein Product Quality.
    Kim M; Ma Y; Srinivasan C; O'Connor T; Telikepalli SN; Ripple DC; Lute S; Bhirde A
    Sci Rep; 2023 Nov; 13(1):20473. PubMed ID: 37993487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.
    Akhunzada ZS; Hubert M; Sahin E; Pratt J
    Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical method development for characterizing ingredient-specific particle size distributions of nasal spray suspension products.
    Thomas BJ; Absar M; Delvadia R; Conti DS; Witzmann K; Guo C
    J Pharm Sci; 2021 Jul; 110(7):2778-2788. PubMed ID: 33713688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals.
    Telikepalli S; Gonzalez K; Dragulin-Otto S; Ripple D; Carrier M; Khan M
    PDA J Pharm Sci Technol; 2019; 73(5):418-432. PubMed ID: 31209163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
    Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Interlaboratory Study to Identify Potential Visible Protein-Like Particle Standards.
    Telikepalli SN; Carrier MJ; Ripple DC; Barnett G; Bhirde A; Bolton D; Bou-Assaf GM; Ferrari E; Leigh S; Levitskaya-Seaman S; Menzen T; Nikels F; Riley A; Saggu M; Sahni N; Vernooij E; Wuchner K
    AAPS PharmSciTech; 2022 Dec; 24(1):18. PubMed ID: 36526853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative laser diffraction method for the assessment of protein subvisible particles.
    Totoki S; Yamamoto G; Tsumoto K; Uchiyama S; Fukui K
    J Pharm Sci; 2015 Feb; 104(2):618-26. PubMed ID: 25449441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Three Flow Imaging Microscopy Instruments for Image Analysis in Evaluating four Types of Subvisible Particle in Biopharmaceuticals.
    Nishiumi H; Deiringer N; Krause N; Yoneda S; Torisu T; Menzen T; Friess W; Uchiyama S
    J Pharm Sci; 2022 Nov; 111(11):3017-3028. PubMed ID: 35948157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Illicit and Counterfeit Drug Analysis by Morphologically Directed Raman Spectroscopy.
    Koutrakos AC; Leary PE; Kammrath BW
    Methods Mol Biol; 2018; 1810():13-27. PubMed ID: 29974414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raman chemical imaging for ingredient-specific particle size characterization of aqueous suspension nasal spray formulations: a progress report.
    Doub WH; Adams WP; Spencer JA; Buhse LF; Nelson MP; Treado PJ
    Pharm Res; 2007 May; 24(5):934-45. PubMed ID: 17372686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Flow Imaging Analysis for Subvisible Particle Characterization in Glatiramer Acetate.
    Levin I; Zigman S; Komlosh A; Kettenring J
    J Pharm Sci; 2015 Nov; 104(11):3977-3983. PubMed ID: 26099719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Silicone Oil-Induced Protein Aggregation with Stimulated Raman Scattering Imaging.
    Wong B; Zhao X; Su Y; Ouyang H; Rhodes T; Xu W; Xi H; Fu D
    Mol Pharm; 2023 Aug; 20(8):4268-4276. PubMed ID: 37382286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products.
    Farias G; Shur J; Price R; Bielski E; Newman B
    AAPS J; 2021 May; 23(4):73. PubMed ID: 34008082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologically-directed Raman spectroscopy for forensic soil analysis.
    Kammrath BW; Koutrakos A; Castillo J; Langley C; Huck-Jones D
    Forensic Sci Int; 2018 Apr; 285():e25-e33. PubMed ID: 29336854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
    Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative High-Throughput Analysis of Subvisible Particles in Biological Formulations Using Backgrounded Membrane Imaging.
    Murphy MI; Bruque M; Hanford A; Trayton I; Handali M; Leissa JA; Hasige S; Day K; Patel SM
    J Pharm Sci; 2022 Jun; 111(6):1605-1613. PubMed ID: 35318031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.